Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

about

Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

Item

http://www.wikidata.org/entity/Q38936565

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

@en

type

Item

label

Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

@en

prefLabel

Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

@en

P1476

Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment

@en

P2093

L C Bollheimer

http://www.w3.org/2001/XMLSchema#string

P Härle

http://www.w3.org/2001/XMLSchema#string

S Schlee

http://www.w3.org/2001/XMLSchema#string

T Bertsch

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Management of hyperuricemia in gout: focus on febuxostat.

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.

Which medications to avoid in people at risk of delirium: a systematic review.

Clinical practice. Gout.

Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group.

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study.

P2888

s00391-017-1199-1

P304

703-710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00391-017-1199-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

C C Sieber

P577

2017-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28246893

http://www.w3.org/2001/XMLSchema#string